Antimicrobial Susceptibility Testing Market: Rising Antimicrobial Resistance Drives Demand for Advanced Diagnostic Solutions
The global Antimicrobial Susceptibility Testing Market is gaining momentum as healthcare providers increasingly prioritize accurate pathogen identification and effective antibiotic treatment. Antimicrobial susceptibility testing (AST) helps determine which antimicrobial medicines can effectively inhibit or eliminate specific microorganisms, supporting clinicians in selecting appropriate treatments. Growing antimicrobial resistance, increasing infectious disease cases, and the need for faster diagnostic results are encouraging hospitals, clinical laboratories, and research institutions to adopt advanced testing technologies.
* Access Exclusive Industry Data: https://www.maximizemarketresearch.com/request-sample/1281/
Antimicrobial Susceptibility Testing Market Estimation, Growth Drivers, and Opportunities
According to Maximize Market Research, the global Antimicrobial Susceptibility Testing Market was valued at USD 6.17 billion in 2025 and is projected to grow at a CAGR of 5.6% from 2026 to 2034, reaching approximately USD 10.08 billion by 2034. The increasing prevalence of bacterial and fungal infections, together with the spread of drug-resistant microorganisms, is a major factor driving demand for susceptibility testing.
The growing need for evidence-based antibiotic selection is encouraging healthcare facilities to strengthen microbiology laboratory capabilities. AST enables clinicians to identify effective treatment options and supports antimicrobial stewardship programs aimed at reducing inappropriate antibiotic use. Technological developments in automated laboratory instruments, molecular diagnostics, and rapid testing platforms are also improving laboratory efficiency and diagnostic workflows.
Significant opportunities are emerging through the development of rapid phenotypic testing, advanced diagnostic software, and integrated laboratory systems. Growing investment in infectious disease surveillance and research into resistant pathogens is expected to create additional demand. However, equipment costs, limited laboratory infrastructure in developing regions, and the need for trained professionals may restrict adoption in some markets.
United States Market Trends and Investments in 2025
The United States continued to demonstrate strong innovation in antimicrobial susceptibility testing during 2025, particularly through regulatory clearances and the introduction of advanced diagnostic systems. In April 2025, Becton, Dickinson and Company (BD) received FDA 510(k) clearance for its BD Phoenix M50 and BDXpert System integration with the BD Synapsys Informatics Solution. The system combines automated microbiology testing and diagnostic interpretation to support the detection of antimicrobial resistance. Thermo Fisher Scientific also received several FDA clearances for its Sensititre antimicrobial susceptibility testing products during 2025, expanding testing options for specific antibiotics and resistance-related applications. In March 2025, bioMérieux received FDA clearance for its VITEK COMPACT PRO identification and antimicrobial susceptibility testing system. These developments demonstrate growing industry investment in laboratory automation, testing accuracy, and faster clinical decision-making.
Antimicrobial Susceptibility Testing Market Segmentation Analysis
The market is segmented by product, type, application, end-user, and method. Based on product, manual antimicrobial susceptibility testing products held the largest market share in 2025. This category includes susceptibility testing disks, MIC strips, and susceptibility testing plates. Their established use in microbiology laboratories, accessibility, and adoption across developing healthcare markets support segment demand. Automated laboratory instruments, culture and growth media, and consumables also represent important product categories.
By type, the market includes antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing, and other susceptibility testing types. Antibacterial testing remains central to clinical microbiology because of the growing need to identify antibiotic-resistant bacterial infections.
By application, the market covers clinical diagnostics, drug discovery and development, epidemiology, and other applications. Clinical diagnostics plays an important role because hospitals and diagnostic laboratories rely on AST results to guide treatment decisions. By end-user, the segments include hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research and academic institutes, and clinical research organizations. The market is further divided by testing method into Etest, disk diffusion, automated susceptibility testing instruments, agar dilution, and genotyping methods.
Antimicrobial Susceptibility Testing Market, Key Players:
1. bioMérieux SA
2. Becton
3. Dickinson and Company
4. Thermo Fisher Scientific
5. Danaher Corporation
6. Bio-Rad Laboratories, Inc.
7. Bruker
8. Roche Diagnostics Limited
9. Accelerate Diagnostics, Inc.
10. Merck KGaA
11. Hi-Media Laboratories
12. Liofilchem S.r.l.
13. Alifax S.r.l.
14. Creative Diagnostics
15. Synbiosis
16. Bioanalyse
17. ZHUHAI DL BIOTECH Co., Ltd.
18. ELITechGroup
19. Mast Group Ltd.
20. CONDALAB
21. Genefluidics, Inc.
22. Biotron Ltd
23. InvivoGen
24. MP Biomedicals
25. QuantaMatrix Inc.
26. PML Microbiologicals Inc.
27. Other key players
Competitive Analysis
The competitive landscape includes established diagnostic and life science companies developing testing platforms, laboratory instruments, and microbiology solutions. Five prominent companies from the MMR report's key-player list are bioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, and Bio-Rad Laboratories. The report identifies these companies as key participants but does not establish a verified ranking of their individual global market shares.
bioMérieux is strengthening its diagnostic portfolio through systems such as VITEK COMPACT PRO, which combines microorganism identification with antimicrobial susceptibility testing. BD is advancing automated microbiology workflows through its Phoenix M50 platform and BDXpert diagnostic interpretation software. Thermo Fisher Scientific continues to develop its Sensititre portfolio, offering manual and automated solutions for MIC-based testing. Danaher participates in the broader clinical diagnostics and laboratory technology market through its diagnostic businesses, while Bio-Rad supports clinical laboratories with diagnostic and quality-control technologies. Continued innovation in automated interpretation, rapid organism identification, expanded antimicrobial panels, and integrated laboratory information systems is expected to strengthen competition and support market development.
Regional Analysis
United States: The United States is a major contributor to market demand, supported by advanced healthcare infrastructure, established diagnostic laboratories, and investment in antimicrobial resistance research. FDA regulatory activity and the adoption of automated diagnostic platforms further encourage innovation.
United Kingdom: Growing attention to antimicrobial resistance surveillance and national antimicrobial stewardship initiatives supports AST adoption. The need for responsible antibiotic use across hospitals and healthcare facilities creates opportunities for diagnostic providers.
Germany and France: Both countries benefit from established healthcare systems, advanced clinical microbiology capabilities, and strong diagnostic technology industries. Research initiatives and European efforts to address antimicrobial resistance support demand for accurate testing solutions.
Japan and China: Japan's advanced healthcare infrastructure and focus on diagnostic precision support the adoption of modern AST systems. China offers growth opportunities through expanding healthcare infrastructure, increasing laboratory capacity, and efforts to improve infectious disease diagnosis. The MMR report identifies North America as the largest regional market in 2025 but does not provide individual country-level market-share percentages for these six countries.
Related Reports:
Global Microplate Washers Market https://www.maximizemarketresearch.com/market-report/global-microplate-washers-market/90798/
Global Ductless Fume Hoods Market https://www.maximizemarketresearch.com/market-report/global-ductless-fume-hoods-market/92036/
Veterinary Dental Equipment Market https://www.maximizemarketresearch.com/market-report/veterinary-dental-equipment-market/249639/
Conclusion
The Antimicrobial Susceptibility Testing Market is positioned for sustained growth as antimicrobial resistance becomes an increasingly important global healthcare challenge. Rising demand for accurate diagnostics, improved laboratory automation, and effective antimicrobial stewardship will remain major growth drivers. In particular, rapid testing technologies that reduce the time required to identify effective treatments represent a significant opportunity. Companies investing in advanced diagnostic platforms, expanded testing capabilities, and integrated laboratory solutions are likely to strengthen their competitive positions as healthcare systems prioritize faster and more informed treatment decisions.
About Maximize Market Research
Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.
Contact Maximize Market Research
MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? sales@maximizemarketresearch.com
